UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 11, 2006
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-15360
Oregon | | 93-1099680 |
(State or other jurisdiction of incorporation | | (I.R.S. Employer Identification No.) |
or organization) | | |
| | |
20245 SW 95th Avenue | | |
Tualatin, Oregon | | 97062 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (503) 692-8001
Former name or former address if changed since last report:
No Change
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
BIOJECT MEDICAL TECHNOLOGIES INC.
FORM 8-K
INDEX
1
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
(b) On August 11, 2006, Ms. Sandra Panem resigned from the Bioject Medical Technologies Inc. (“Bioject”) Board of Directors.
(d) On August 11, 2006, Mr. John Gandolfo was elected as a director of Bioject. Mr. Gandolfo was appointed to act as a member of the Ad-Hoc Financing Committee. Mr. Gandolfo’s employment as Chief Financial Officer of Bioject was terminated effective May 3, 2006 as part of Bioject’s previously announced plan of restructuring. In connection with Mr. Gandolfo’s departure, Bioject agreed to pay Mr. Gandolfo $380,749 in cash severance over a 12 month period and accelerated the vesting of 41,125 non-vested stock awards held by Mr. Gandolfo.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: August 15, 2006 | BIOJECT MEDICAL TECHNOLOGIES INC. |
| (Registrant) |
| |
| |
| /s/ CHRISTINE M. FARRELL | |
| Christine M. Farrell |
| Vice President of Finance |
| (Principal Financial and Accounting Officer) |
3
